Cover Image
市場調查報告書

Nabriva Therapeutics AG:產品平台分析

Nabriva Therapeutics AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192722
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Nabriva Therapeutics AG:產品平台分析 Nabriva Therapeutics AG - Product Pipeline Review - 2015
出版日期: 2015年03月11日 內容資訊: 英文 26 Pages
簡介

Nabriva Therapeutics AG是開發用來治療受傷及二次感染的異位性皮膚炎,膿痂疹,粉刺,眼睛感染疾病等各種病原菌造成的感染疾病的Pleuromutilin抗生素之生物科技企業。

本報告提供Nabriva Therapeutics AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,以及最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Nabriva Therapeutics AG的基本資料

Nabriva Therapeutics AG概要

  • 主要資訊
  • 企業資料

Nabriva Therapeutics AG:R&D概要

  • 主要的治療範圍

Nabriva Therapeutics AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Nabriva Therapeutics AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品前臨床階段的產品/聯合治療模式

Nabriva Therapeutics AG:藥物簡介

  • BC-3781
  • BC-7013
  • Small Molecules to Inhibit 23S Ribosomal RNA for Infections

Nabriva Therapeutics AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Nabriva Therapeutics AG:最近的開發平台趨勢

Nabriva Therapeutics AG:暫停中的計劃

Nabriva Therapeutics AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06848CDB

Summary

Global Markets Direct's, 'Nabriva Therapeutics AG - Product Pipeline Review - 2015', provides an overview of the Nabriva Therapeutics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nabriva Therapeutics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Nabriva Therapeutics AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Nabriva Therapeutics AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Nabriva Therapeutics AG's pipeline products

Reasons to buy

  • Evaluate Nabriva Therapeutics AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Nabriva Therapeutics AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Nabriva Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Nabriva Therapeutics AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nabriva Therapeutics AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Nabriva Therapeutics AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Nabriva Therapeutics AG Snapshot
    • Nabriva Therapeutics AG Overview
    • Key Information
    • Key Facts
  • Nabriva Therapeutics AG - Research and Development Overview
    • Key Therapeutic Areas
  • Nabriva Therapeutics AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Nabriva Therapeutics AG - Pipeline Products Glance
    • Nabriva Therapeutics AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Nabriva Therapeutics AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Nabriva Therapeutics AG - Drug Profiles
    • lefamulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-7013
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 23S Ribosomal RNA for Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nabriva Therapeutics AG - Pipeline Analysis
    • Nabriva Therapeutics AG - Pipeline Products by Target
    • Nabriva Therapeutics AG - Pipeline Products by Route of Administration
    • Nabriva Therapeutics AG - Pipeline Products by Molecule Type
    • Nabriva Therapeutics AG - Pipeline Products by Mechanism of Action
  • Nabriva Therapeutics AG - Recent Pipeline Updates
  • Nabriva Therapeutics AG - Dormant Projects
  • Nabriva Therapeutics AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Nabriva Therapeutics AG, Key Information
  • Nabriva Therapeutics AG, Key Facts
  • Nabriva Therapeutics AG - Pipeline by Indication, 2015
  • Nabriva Therapeutics AG - Pipeline by Stage of Development, 2015
  • Nabriva Therapeutics AG - Monotherapy Products in Pipeline, 2015
  • Nabriva Therapeutics AG - Phase II, 2015
  • Nabriva Therapeutics AG - Phase I, 2015
  • Nabriva Therapeutics AG - Preclinical, 2015
  • Nabriva Therapeutics AG - Pipeline by Target, 2015
  • Nabriva Therapeutics AG - Pipeline by Route of Administration, 2015
  • Nabriva Therapeutics AG - Pipeline by Molecule Type, 2015
  • Nabriva Therapeutics AG - Pipeline Products by Mechanism of Action, 2015
  • Nabriva Therapeutics AG - Recent Pipeline Updates, 2015
  • Nabriva Therapeutics AG - Dormant Developmental Projects,2015
  • Nabriva Therapeutics AG, Subsidiaries

List of Figures

  • Nabriva Therapeutics AG - Pipeline by Top 10 Indication, 2015
  • Nabriva Therapeutics AG - Pipeline by Stage of Development, 2015
  • Nabriva Therapeutics AG - Monotherapy Products in Pipeline, 2015
  • Nabriva Therapeutics AG - Pipeline by Top 10 Target, 2015
  • Nabriva Therapeutics AG - Pipeline by Top 10 Route of Administration, 2015
  • Nabriva Therapeutics AG - Pipeline by Top 10 Molecule Type, 2015
  • Nabriva Therapeutics AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top